Literature DB >> 8274595

The changing epidemiology of infections at cancer hospitals.

B S Koll1, A E Brown.   

Abstract

Intensive chemotherapy regimens, widespread prophylactic and therapeutic administration of antibiotics, reliance on intravascular catheters, increased use of immunomodulators, and increased outpatient management have altered the epidemiology of infections in patients with neoplastic disease. At many centers, bacteremias due to gram-positive organisms have replaced bacteremias due to gram-negative organisms as the most frequent infections in patients with cancer. Isolation of gram-negative bacilli other than Enterobacteriaceae and Pseudomonas aeruginosa has increased in frequency, and these organisms have become important pathogens. Fungal infections have become a leading cause of morbidity and mortality, and nosocomial fungemias have become more common than nosocomial bacteremias due to gram-negative bacilli in some centers. Mycobacterium tuberculosis, Pneumocystis carinii, and rubeola virus have reemerged as disease-causing entities in patients with cancer. Multiresistant organisms have developed over the past decade. Anticipated trends in infections in patients with cancer also are discussed.

Entities:  

Mesh:

Year:  1993        PMID: 8274595     DOI: 10.1093/clinids/17.supplement_2.s322

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  13 in total

1.  Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients.

Authors:  G Bodey; D Abi-Said; K Rolston; I Raad; E Whimbey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

2.  Comparison of activities of broad-spectrum beta-lactam compounds against 1,128 gram-positive cocci recently isolated in cancer treatment centers.

Authors:  D J Diekema; S L Coffman; S A Marshall; M L Beach; K V Rolston; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

3.  Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline.

Authors:  I Raad; R Hachem; H Hanna; E Girgawy; K Rolston; E Whimbey; R Husni; G Bodey
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 4.  The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens.

Authors:  Sohn Kim; April Covington; Eric G Pamer
Journal:  Immunol Rev       Date:  2017-09       Impact factor: 12.988

5.  Synergism between the antifungal agents amphotericin B and alkyl glycerol ethers.

Authors:  M P Haynes; H R Buckley; M L Higgins; R A Pieringer
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

6.  Etiology and clinical course of febrile neutropenia in children with cancer.

Authors:  Hana Hakim; Patricia M Flynn; Katherine M Knapp; Deo Kumar Srivastava; Aditya H Gaur
Journal:  J Pediatr Hematol Oncol       Date:  2009-09       Impact factor: 1.289

7.  Elisa based diagnostic test for Aspergillosis.

Authors:  G L Sharma; P U Sarma
Journal:  Indian J Clin Biochem       Date:  1997-12

8.  Nature and outcome of febrile episodes in patients with pancreatic and hepatobiliary cancer.

Authors:  K V Rolston; N Dholakia; S Rodriguez; E B Rubenstein
Journal:  Support Care Cancer       Date:  1995-11       Impact factor: 3.603

9.  TNF alpha, IL-1 beta and IL-6 plasma levels in neutropenic patients after onset of fever and correlation with the C-reactive protein (CRP) kinetic values.

Authors:  J L Herrmann; H Blanchard; P Brunengo; P H Lagrange
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

Review 10.  Clinical characteristics of Staphylococcus epidermidis: a systematic review.

Authors:  Amirmorteza Ebrahimzadeh Namvar; Sara Bastarahang; Niloufar Abbasi; Ghazaleh Sheikhi Ghehi; Sara Farhadbakhtiarian; Parastoo Arezi; Mahsa Hosseini; Sholeh Zaeemi Baravati; Zahra Jokar; Sara Ganji Chermahin
Journal:  GMS Hyg Infect Control       Date:  2014-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.